Alpha‐lipoic acid for diabetic peripheral neuropathy
Referencias
Additional references
Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha‐lipoic: the SYDNEY trial. Diabetes Care 2003;26(3):770‐6.
Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. Quarterly Journal of Medicine 1998;91(11):733‐7.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414(6865):813‐82.
Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. Journal of Pain and Symptom Management 2000;20:449‐58.
Creager MA, Luscher TF, Cosentino F, Beckman H. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003;108(12):1527‐32.
DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. New England Journal of Medicine 1993;329(14):977‐86.
Duhmke R, Cornblath D, Hollingshead J. Tramadol for neuropathic pain. Cochrane Database of Systematic Reviews 2004;2:CD003726.
Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. Journal of Clinical Investigation 2003;111(4):431‐3.
Fernyhough P, Huang TJ, Verkhratsky A. Mechanism of mitochondrial dysfunction in diabetic sensory neuropathy. Journal of the Peripheral Nervous System 2003;8(4):227‐35.
Forsblom CM, Sane T, Groop P‐H, Totterman KJ, Kallio M, Saloranta C, et al. Risk factors for mortality in type 2 diabetes: evidence of a role for neuropathy and a protective effect of HLA‐DR4. Diabetologia 1998;41(11):1253‐62.
Gale EAM, Anderson JV. Diabetes mellitus and other disorders of metabolism. In: Kumar P, Clark M editor(s). Clinical Medicine. London: W. B. Saunders, 2002.
Jacob S, Henrikson EJ, Tritschler HJ, Augustin HJ, Dietze GJ. Improvement of insulin stimulated glucose disposal in type 2 diabetes after repeated administration of thioctic acid. Experimental and Clinical Endocrinology & Diabetes 1996;104:284‐8.
Low PA, Nickander KK, Tritscler HJ. The roles of oxidative stress and antioxidant treatment in experimental neuropathy. Diabetes 1997;46(Suppl 2):S38‐S42.
Marchettini P, Teloni L, Formaglio F, Lacerenza M. Pain in diabetic neuropathy case study: whole patient management. European Journal of Neurology 2004;11(Suppl 1):12‐21.
Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004;328(7446):991.
Dukes MNG, Aronson JK, editors. Meyler's Side Effects of Drugs: an encyclopedia of adverse reactions and interactions. 14th Edition. Amsterdam: Elsevier, 2000.
Morikawa T, Yasuno R, Wada H. Do mammalian cells synthesize lipoic acid? Identification of a mouse cDNA encoding a lipoic acid synthase located in mitochondria. FEBS Letters 2001;498(1):16‐21.
Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler H, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995;18(8):1160‐7.
Nicolucci A, Carinci F, Cavaliere D, Scorpiglione N, Belfiglio M, Labbrozi D, et al. A meta‐analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration. Diabetes Medicine 1996;13(12):1017‐26.
Oates PJ. Polyol pathway and diabetic peripheral neuropathy. International Review of Neurobiology 2002;50:325‐92.
Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001;17(10):888‐95.
Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past present and future. Diabetes 1995;44(12):1355‐61.
Pirart J. Tight glycaemic control prevents diabetic complications. Acta Clinica Belgica 1995;50(6):321‐5.
Snell EE, Strong FM, Peterson WH. Growth factors for bacteria. VI: Fractionation and properties of an accessory factor for lactic acid bacteria. Biochemistry 1937;31:1789.
Soliman E, Gellido C. Diabetic Neuropathy. eMedicine.com March 29, 2002.
Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy ‐ a continuing enigma. Diabetes Metabolism Research and Reviews 2000;16(6):408‐33.
Tomlinson DR, Willars GB, Carrington AL. Aldose reductase inhibitors and diabetic complications. Pharmacology & Therapeutics 1992;54(2):151‐94.
van Dam PS. Oxidative stress and diabetic neuropathy:pathophysiological mechanisms and treatment. Diabetes Metabolism Research Reviews 2002;18(3):176‐84.
WHO Diagnosis and Classification of Diabetes Mellitus. WHO Department of Noncommunicable Disease Surveillance1999.
Wild S, Roglic G, Sicree R, Green A, King H. Global burden of diabetes mellitus in the year 2000. The World Health Report 2001. World Health Organization, 2001.
Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36(2):150‐4.
Ziegler D, Reljanovic D, Mehnert H, Gries FA. Alpha‐Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Experimental & Clinical Endocrinolgy & Diabetes 1999;107(7):421‐30.
Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha‐lipoic acid: a meta‐analysis. Diabetes Medicine 2004;21(2):114‐21.
